Abstract
The diffuse lymphocyte infiltration of target organs in Sjögren’s syndrome seems potentially amenable to therapies which might alter specific lymphocyte populations or their migration to tissues. Especially because this illness responds unsatisfactorily to conventional immunosuppression, efforts are underway to ameliorate disease using monoclonal antibodies, cytokines, and gene therapy. Promising data have been obtained using B-cell depletion with monoclonal antibodies, although further trials are necessary. Because B-cell homeostasis depends to a large degree on the cytokine BAFF/Blys, blocking of these molecules or their receptors may be a valuable approach in some patients. In Sjögren’s syndrome, the activation of interferon type I genes has opened the possibility that blocking antibodies to interferon-α or interferon-β may interrupt the disease process and reduce lymphocytic tissue infiltration. Monoclonal antibodies to adhesion molecules and other structures affecting lymphocyte homing may be particularly useful in this illness as well as antibodies to cytokines and their receptors, such as IL-6. Co-stimulation blockade using CTLA-4 is worthy of consideration for Sjögren’s syndrome treatment, in light of the important role for T cells in this illness. Finally, while far from clinical use, the delivery of cytokines such as IL-10 by viral vectors or other forms of gene therapy is also an appealing approach. The next few years should bear witness to important new, rational biological approaches to Sjögren’s syndrome which should increase our understanding of its basis and provide welcome relief for patients with severe illness.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barone F, Bombardieri M, Manzo A, Blades MC, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren’s syndrome. Arthritis Rheum. 2005;52:1773–184.
Fox RI, Adamson TC 3rd, Fong S, Young C, Howell FV. Characterization of the phenotype and function of lymphocytes infiltrating the salivary gland in patients with primary Sjögren syndrome. Diagn Immunol. 1983;1:233–9.
Soliotis FC, Moutsopoulos HM. Sjögren’s syndrome. Autoimmunity 2004;37:305–7.
Manganelli P, Fietta P. Apoptosis and Sjögren syndrome. Semin Arthritis Rheum. 2003;33:49–65.
Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren’s syndrome: a pilot study. Arthritis Rheum. 2001;44:2371–5.
Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjögren’s syndrome: one-year follow up. Arthritis Rheum. 2002;46:3301–3.
Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren’s Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–6.
Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjögren’s syndrome: a pilot study. J Rheumatol. 2004;31:96–101.
Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–5.
Batten M, Fletcher C, Ng LG, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol. 2004;172:812–22.
Mavragani CP, Niewold TB, Moutsopoulos N, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjögren’s syndrome treated with etanercept. Arthritis Rheum. 2007;56:3995–4004.
Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis. 2008;67:1437–43.
Thanou-Stavraki A, James JA. Primary Sjögren’s syndrome: current and prospective therapies. Semin Arthritis Rheum. 2008;37:273–92.
Le Pottier L, Devauchelle V, Pers JO, Jamin C, Youinou P. The mosaic of B-cell subsets (with special emphasis on primary Sjögren’s syndrome). Autoimmun Rev. 2007;6:149–54.
Jonsson V, Wiik A, Hou-Jensen K, et al. Autoimmunity and extranodal lymphocytic infiltrates in lymphoproliferative disorders. J Intern Med. 1999;245:277–86.
Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol. 2004;16:180–5.
Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740–50.
Pijpe JG. van Imhoff W, Vissink A, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren’s syndrome and associated MALT lymphoma. Ann Rheum Dis. 2005;64:958–60.
Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913–20.
Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis. 2007;66:351–7.
Devauchelle-Pensec V, PennecY, Morvan J, et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310–7.
Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010.62(4):960–8.
St. Clair E, Levesque MC, Luning Prak N, Vivino FB, AlapattC, Wallace D, Cohen P. Rituximab therapy for primary Sjögren’s syndrome (pSS): an open-label trial. Arthritis Rheum. 2007;56(Suppl 9):S449 (abst).
Levesque M, Luning Prak N, St. Clair EW, et al. Longitudinal analysis of lymphocyte subsets in patients with primary Sjögren’s syndrome (pSS) treated with rituximab: results from an open-label clinical trial. Arthritis Rheum. 2007;56(Suppl 9):S445.
Cohen P, Silverman G, Peck AB, Cornelius JG, Luning Prak N, Levesque MC, Vivino F, Srikishnan R, St. Clair EW. IgA autoantibodies fall selectively in B-cell depleted Sjogren patients. Ann Rheum Dis. 2008;67:214 (abst).
Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007;44:1331–41.
Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8:R129.
Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome. J Clin Invest. 2002;109:59–68.
Lodde BM, Baum BJ, Tak PP, Illei G. Experience with experimental biological treatment and local gene therapy in Sjögren’s syndrome: implications for exocrine pathogenesis and treatment. Ann Rheum Dis. 2006;65:1406–13.
Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, Di Pucchio T, Connolly J, Fay JW, Pascual V, Palucka AK, Banchereau J. Dendritic cell subsets in health and disease. Immunol Rev. 2007;219:118–42.
Ronnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008;17:394–9.
Nordmark G, Alm GV, Ronnblom L. Mechanisms of disease: primary Sjögren’s syndrome and the type I interferon system. Nat Clin Pract Rheumatol. 2006;2:262–9.
Wallace D, Petri M, Olsen N, et al. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum. 2007;56(Suppl 9):S526.
Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB. Treatment of primary Sjögren’s syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res. 1999;19:943–51.
Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsutsui MT, Tak PP, Chiorini JA, Baum BJ. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren’s syndrome. Hum Gene Ther. 2003;14:1605–18.
Zhu Z, Stevenson D, Ritter T, Schechter JE, Mircheff AK, Kaslow HR, Trousdale MD. Expression of IL-10 and TNF-inhibitor genes in lacrimal gland epithelial cells suppresses their ability to activate lymphocytes. Cornea 2002;21:210–4.
Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP, Baum BJ. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjögren’s syndrome. Ann Rheum Dis. 2006;65:195–200.
Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Teng J, Becker JC, Westhovens R. Results of a two-year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008;58:953–63.
Fox RI. Clinical features, pathogenesis, and treatment of Sjögren’s syndrome. Curr Opin Rheumatol. 1996;8:438–45.
Gottenberg JE, Loiseau P, Azarian M, Chen C, Cagnard N, Hachulla E, Puechal X, Sibilia J, Charron D, Mariette X, Miceli-Richard C. CTLA-4 + 49A/G and CT60 gene polymorphisms in primary Sjogren syndrome. Arthritis Res Ther. 2007;9:R24.
Meyer MA. Natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:2387–9; author reply 87–9.
Weissert R. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived. Expert Rev Neurother. 2006;6:1587–90.
Marecki S, Kirkpatrick P. Efalizumab. Nat Rev Drug Discov. 2004;3:473–4.
Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA. 2005;102:2075–80.
Ohsugi Y, Kishimoto T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2008;8:669–81.
Tishler M, Yaron I, Geyer O, Shirazi I, Naftaliev E, Yaron M. Elevated tear interleukin-6 levels in patients with Sjogren syndrome. Ophthalmology 1998;105:2327–9.
Further Reading
Abdulahad WH, Meijer JM, Kroese FG, Meiners PM, Vissink A, Spijkervet FK, Kallenberg CG, Bootsma H. B-cell reconstitution and T-helper-cell balance after rituximab treatment of active primary Sjögren’s syndrome. Arthritis Rheum. 2011 Jan; 10. [Epub ahead of print]
Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis. 2009 Feb;68(2):284–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Cohen, P.L., Traisak, P. (2011). Biological Treatment for Sjögren’s Syndrome. In: Fox, R., Fox, C. (eds) Sjögren’s Syndrome. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-957-4_32
Download citation
DOI: https://doi.org/10.1007/978-1-60327-957-4_32
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-60327-956-7
Online ISBN: 978-1-60327-957-4
eBook Packages: MedicineMedicine (R0)